Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity
Top Cited Papers
- 21 June 2004
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 101 (26) , 9804-9809
- https://doi.org/10.1073/pnas.0403492101
Abstract
We investigated the contributions of the structural proteins of severe acute respiratory syndrome (SARS) coronavirus (CoV) to protective immunity by expressing them individually and in combinations from a recombinant parainfluenza virus (PIV) type 3 vector called BHPIV3. This vector provided direct immunization of the respiratory tract, the major site of SARS transmission, replication, and disease. The BHPIV3/SARS recombinants were evaluated for immunogenicity and protective efficacy in hamsters, which support a high level of pulmonary SARS-CoV replication. A single intranasal administration of BHPIV3 expressing the SARS-CoV spike protein (S) induced a high titer of SARS-CoV-neutralizing serum antibodies, only 2-fold less than that induced by SARS-CoV infection. The expression of S with the two other putative virion envelope proteins, the matrix M and small envelope E proteins, did not augment the neutralizing antibody response. In absence of S, expression of M and E or the nucleocapsid protein N did not induce a detectable serum SARS-CoV-neutralizing antibody response. Immunization with BHPIV3 expressing S provided complete protection against SARS-CoV challenge in the lower respiratory tract and partial protection in the upper respiratory tract. This was augmented slightly by coexpression with M and E. Expression of M, E, or N in the absence of S did not confer detectable protection. These results identify S among the structural proteins as the only significant SARS-CoV neutralization antigen and protective antigen and show that a single mucosal immunization is highly protective in an experimental animal that supports efficient replication of SARS-CoV.Keywords
This publication has 34 references indexed in Scilit:
- Progress in the Development of Respiratory Syncytial Virus and Parainfluenza Virus VaccinesClinical Infectious Diseases, 2003
- The Genome Sequence of the SARS-Associated CoronavirusScience, 2003
- Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory SyndromeScience, 2003
- Roles for the Cytoplasmic Tails of the Fusion and Hemagglutinin-Neuraminidase Proteins in Budding of the Paramyxovirus Simian Virus 5Journal of Virology, 2002
- Mucosal Immunization of Rhesus Monkeys against Respiratory Syncytial Virus Subgroups A and B and Human Parainfluenza Virus Type 3 by Using a Live cDNA-Derived Vaccine Based on a Host Range-Attenuated Bovine Parainfluenza Virus Type 3 Vector BackboneJournal of Virology, 2002
- The Missing Link in Coronavirus AssemblyJournal of Biological Chemistry, 2001
- Assembly of Spikes into Coronavirus Particles Is Mediated by the Carboxy-Terminal Domain of the Spike ProteinJournal of Virology, 2000
- Envelope glycoprotein interactions in coronavirus assembly.The Journal of cell biology, 1995
- A Live Attenuated Bovine Parainfluenza Virus Type 3 Vaccine Is Safe, Infectious, Immunogenic, and Phenotypically Stable in Infants and ChildrenThe Journal of Infectious Diseases, 1995
- Antibody-mediated enhancement of disease in feline infectious peritonitis: Comparisons with dengue hemorrhagic feverComparative Immunology, Microbiology and Infectious Diseases, 1981